Stockscreener 앱 받기
54.32
2.60%
-1.45
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious - Benzinga
BMS Delivers Q3 Beat, Raises 2024 Guidance Amid Strong Demand for Legacy and Newer Drugs - BioSpace
Bristol-Myers Squibb Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic ... - Yahoo Finance
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY) - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
A promising schizophrenia drug showed mixed results. What does that mean for patients?WGN Radio - WGN Radio - Chicago
December 13th Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript - The Motley Fool
Bristol Myers earnings beat expectations, driven by sales of older drugs - Reuters
Bristol Myers earnings beat expectations, driven by sales of older drugs By Reuters - Investing.com
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024 - BioSpace
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View - Nasdaq
Bristol Myers Squibb stock rises, Merck moves lower. Here's why. - Yahoo Finance
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit - Benzinga
Bristol Myers Q3 earnings beat expectations, helped by sales of older drugs - PharmaLive
Bristol Myers’s stock pops as earnings top estimates and company raises guidance - MarketWatch
Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Bristol-Myers hikes annual earnings guidance as Q3 exceeds expectations; shares up - MSN
Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings: Revenue Surpasses Estimates at $11.9 Billion, GAAP EPS at $0.60 - GuruFocus.com
Bristol Myers Squibb's Earnings Surpass Expectations With Strong Drug Sales - Finimize
Bristol-Myers raises outlook ahead of consensus after Q3 beat - MSN
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance
Bristol Myers: Q3 Earnings Snapshot - The Washington Post
Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance - MSN
Bristol-Myers Squibb Co. Q3 Profit Decreases, But Beats Estimates - Nasdaq
Bristol-Myers Squibb earnings beat by $0.30, revenue topped estimates - Investing.com South Africa
Bristol Raises Guidance on Demand for Eliquis, New Drugs - BNN Bloomberg
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs - CNBC
Bristol-Myers Squibb Q3 24 Earnings Conference Call At 8:00 AM ET - Nasdaq
Areas of interest - Bristol Myers Squibb
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Drugmakers urge appeals court to revive challenge to US drug price negotiation program - Reuters
Bristol Myers Squibb Q3 2024 Earnings Preview: Profit decline anticipated - MSN
Is Eli Lilly Stock a Buy? - The Motley Fool
Jim Cramer Says Bristol-Myers Squibb Company (BMY) Is ‘Too Low’ - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings? - MSN
Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts? - Yahoo Finance
UTSA announces partnership with Bristol Myers Squibb to advance pharmaceutical discoveries and development - The University of Texas at San Antonio
Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024 - StockTitan
Shareholders in Bristol-Myers Squibb (NYSE:BMY) are in the red if they invested three years ago - Simply Wall St
Psoriasis around the world - Bristol Myers Squibb
Allspring Global Investments Holdings LLC Has $11.12 Million Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Second Circuit Weighs Whether Bristol-Myers Delayed Cancer Drug - Bloomberg Law
Citigroup downgrades Bristol-Myers Squibb to 'neutral' - XM
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
People and business resource groups - Bristol Myers Squibb
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
December 6th Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Bristol-Myers Squibb's SWOT analysis: stock faces challenges amid new approvals - Investing.com
Spain CAR-T Cell Therapy Market Forecast to 2029, Featuring - GlobeNewswire
Spain CAR-T Cell Therapy Market Forecast to 2029, Featuring Strategic Profiles of Gilead Sciences, Novartis Int'l, Bristol Myers Squibb, AbbVie, AMGEN, Pfizer, Merck & Co, Johnson & Johnson - Yahoo Finance
0.78%
0.74%
자본화:
|
볼륨(24시간):